FOLH1 and prostate carcinoma: We plan to evaluate the safety of SBRT with PSMA PET/MRI-guided focal boost in a prospective early phase trial, “PSMA MRI Guided prOstate SBRT(ARGOS).” As noted, while the advanced imaging techniques described show promise for the characterization of primary or recurrent prostate cancer, no study has prospectively and longitudinally evaluated them after primary radiotherapy to characterize expected changes in response to treatment and to non-invasively identify early treatment failure.